Kathleen McElhone

Novartis (Switzerland) — Switzerland

Immunology and Microbiology · Life Sciences

26h-index3.1kcitations74works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Psoriasis: Treatment and Pathogenesis(42), Dermatology and Skin Diseases(26), Systemic Lupus Erythematosus Research(22), Pharmaceutical studies and practices(11), Health Systems, Economic Evaluations, Quality of Life(9)

Publications73 total

Evaluating changes in baseline characteristics and drug-utilization pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) cohort
Clinical and Experimental Dermatology·2025· 2 citedOpen Access
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
British Journal of Dermatology·2025· 3 citedOpen Access
Risk of suicide and suicidality in patients with moderate to severe psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
Clinical and Experimental Dermatology·2024· 2 citedOpen Access
PS04 Suicide risk in patients with psoriasis: results from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
British Journal of Dermatology·2024Open Access
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
British Journal of Dermatology·2023· 15 citedOpen Access
Characteristics of ‘super responders’ and ‘super nonresponders’ to first biologic monotherapy for psoriasis: a nested case–control study
British Journal of Dermatology·2023· 12 citedOpen Access
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics
Journal of Allergy and Clinical Immunology·2023· 17 citedOpen Access
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)
British Journal of Dermatology·2023· 6 citedOpen Access
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR
British Journal of Dermatology·2023· 20 citedOpen Access
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatology·2022· 136 citedOpen Access
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis
Journal of Investigative Dermatology·2021· 30 citedOpen Access
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies
Journal of the European Academy of Dermatology and Venereology·2021· 5 citedOpen Access
Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR
Journal of the European Academy of Dermatology and Venereology·2021· 6 citedOpen Access
Assessment of Health-Related Quality of Life in Systemic Lupus Erythematosus
2021· 1 cited
Untitled
CLOK (University of Central Lancashire)·2020· 9 citedOpen Access
Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study
Journal of Investigative Dermatology·2020· 11 citedOpen Access
Issue Information
Journal of the European Academy of Dermatology and Venereology·2020Open Access
Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
Journal of the European Academy of Dermatology and Venereology·2019· 51 citedOpen Access
Persistence and effectiveness of systemic therapies for psoriasis
British Journal of Dermatology·2019· 1 citedOpen Access
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis
British Journal of Dermatology·2019· 25 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

C.E.M. Griffiths(43), Richard B. Warren(39), Catherine Smith(34), Nick J. Reynolds(32), Juliet N. Barker(25), Zenas Z N Yiu(23), K.J. Mason(20), A. David Burden(18), Mark Lunt(18), Brian Kirby(18), Anthony D. Ormerod(17), Ruth Murphy(16), Oras Alabas(15), Caroline Owen(14), Darren M. Ashcroft(12), Philip Laws(12), Anthony Bewley(12), Janice Abbott(11), Ian Evans(10), Teena Mackenzie(10)